These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16172771)

  • 1. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    Tavintharan S; Lim SC; Sum CF
    Singapore Med J; 2005 Oct; 46(10):519-28. PubMed ID: 16172771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low HDL-C: a secondary target of dyslipidemia therapy.
    Rosenson RS
    Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    Neth J Med; 2004; 62(7):229-34. PubMed ID: 15554597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Wierzbicki AS
    Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of fibrates in reducing coronary risk: a UK Consensus.
    UK HDL-C Consensus Group
    Curr Med Res Opin; 2004; 20(2):241-7. PubMed ID: 15006019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein metabolism: potential therapeutic targets.
    Davidson MH; Toth PP
    Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-density lipoprotein: a new target in the battle against atherothrombotic disease].
    Hansen PR
    Ugeskr Laeger; 2006 Jan; 168(5):468-70. PubMed ID: 16472435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.